NCR3 and neoplasm: Further examination revealed that Tocilizumab treatment markedly upregulated NKp30 expression on NK92 cells within the tumor microenvironment (Supplementary Fig. 7c) and enhanced their granzyme B secretion capacity (Supplementary Fig. 7d).